Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dropout rates with olanzapine or risperidone: a multi-centre observational study.

F Pelagotti1, B Santarlasci, F Vacca

  • 1Laboratorio SIFO di Farmacoeconomia, Drug Information Centre, Azienda Ospedaliera Careggi, viale Morgagni 85, 50134 Florence, Italy.

European Journal of Clinical Pharmacology
|December 20, 2003
PubMed
Summary

Olanzapine may lead to fewer treatment discontinuations compared to risperidone in schizophrenia patients. This observational study confirms findings suggesting olanzapine offers a lower risk of dropout.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spiropyran-based glutamate nanovalve for neuronal stimulation.

Materials horizons·2025
Same author

Solid-State Nanopores for Spatially Resolved Chemical Neuromodulation.

Nano letters·2024
Same author

Treatments for relapsed-refractory diffuse large B-cell lymphoma: comparison of overall survival outcomes observed with four novel agents.

European review for medical and pharmacological sciences·2022
Same author

Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors.

European review for medical and pharmacological sciences·2021
Same author

Incidence of low-titre factor VIII inhibitors in patients with haemophilia A: meta-analysis of observational studies.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Meta-Analysis: Limits and Benefits.

Clinical drug investigation·2016

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Research

Background:

  • Risperidone and olanzapine are common atypical antipsychotics for schizophrenia.
  • Previous meta-analysis indicated olanzapine may have lower discontinuation rates than risperidone.
  • Observational studies are needed to validate these findings in real-world patient populations.

Purpose of the Study:

  • To compare treatment discontinuation rates between olanzapine and risperidone in schizophrenia patients.
  • To assess if olanzapine's potential advantage in reducing dropout is observable in a clinical setting.
  • To validate previous meta-analysis findings through a multi-center observational study.

Main Methods:

  • Retrospective, multi-center observational study design.

Related Experiment Videos

  • Inclusion of patients with stable olanzapine or risperidone treatment for at least 4 months.
  • Data collection included demographics, current and previous antipsychotic treatments, dosage, and duration.

    • Main Results:

    • Primary analysis (7 months) showed significantly fewer switches from olanzapine to risperidone (4/54) than from risperidone to olanzapine (11/40, P=0.01).
    • Secondary analysis (up to 73 months) revealed similar trends: 9/236 switches from olanzapine to risperidone vs. 17/150 from risperidone to olanzapine (P=0.004).
    • These results indicate a lower dropout rate for olanzapine compared to risperidone.

    Conclusions:

    • Olanzapine appears to be associated with a lower risk of treatment discontinuation than risperidone.
    • The study supports previous meta-analysis findings in an observational context.
    • Findings suggest olanzapine may be a preferred option for maintaining long-term treatment adherence in schizophrenia.